26th Mar 2025 07:45
26 March 2025
GENinCode Plc
("GENinCode" or the "Company")
Grant of Share Options & PDMR Dealings
GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that on 21 March 2025 the Company approved the grant of options over an aggregate of 14,028,305 new ordinary shares of 1 pence each in the Company ('Ordinary Shares') under the 2021 Share Option Plan ('2021 Share Option Plan') to certain directors and employees of the Company (the "New Options"), representing 4.89% per cent. of the Company's existing issued share capital.
Terms of the New Options
The Company adopted the 2021 Share Option Plan to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. 14,028,305 New Options will be issued at an exercise price of 3.7 pence per share which are exercisable on the second anniversary of the date of grant. There are no other vesting criteria for the New Options which have a 10-year term.
Details of resultant holdings
Following the New Options grant and the Option Surrender, details of Options held by Directors, PDMRs and other employees of the Company, are as follows:
Director's name | Position | Number of New Options granted at 3.7 pence | Aggregate number of options post grant | Current total beneficial holding of Ordinary Shares | Current holding as a % of Issued share capital |
Matthew Walls | CEO | 2,431,082 | 5,254,832 | 12,235,473 | 4.26% |
Paul Foulger | CFO | 2,216,062 | 4,790,062 | 1,273,587 | 0.44% |
Jordi Puig | COO | 1,462,524 | 3,161,274 | 14,737,636 | 5.14% |
William Rhodes | Non-Executive Chair | 554,016 | 1,197,516 | - | 0.0% |
Huon Gray | Non-Executive Director | 387,423 | 837,423 | 905,405 | 0.32% |
Felix Frueh | Non-Executive Director | 387,423 | 837,423 | 100,000 | 0.03% |
Sergio Olivero | Non-Executive Director | 172,188 | 172,188 | 7,417,243 | 2.59% |
Other Employees | 6,417,587 | 16,912,905 |
N/A |
N/A | |
Total: |
| 12,640,526 | 32,991,435 | 36,669,344 | 12.78% |
Following the grant of the New Options, there are Options over a total of 32,915,560 Ordinary Shares in the Company as at the date of this announcement, representing approximately 11.47% of the Company's existing issued share capital.
For more information visit www.genincode.com
Enquiries:
GENinCode Plc | www.genincode.com or via Walbrook PR |
| |
Matthew Walls, CEO |
| ||
Paul Foulger, CFO
|
| ||
Cavendish Capital Markets Limited | Tel: +44 (0)20 7397 8900 |
| |
Giles Balleny /Dan Hodkinson (Corporate Finance) Dale Bellis / Michael Johnson (Sales) Nigel Birks (Life Sciences Specialist Sales) Ondraya Swanson (Corporate Broking)
| |||
| |||
Walbrook PR Limited Anna Dunphy / Paul McManus / Louis Ashe-Jepson |
Tel: 020 7933 8780 or [email protected] |
| |
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.
The notification set out below is provided in accordance with the requirements of MAR.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||
a. | Name | 1. Matthew Walls 2. Paul Foulger 3. Jordi Puig 4. William Rhodes 5. Huon Gray 6. Felix Frueh 7. Sergio Olivero
| |||||||
2 | Reason for notification |
| |||||||
a. | Position/Status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Chief Operating Officer 4. Non-Executive Chair 5. Non-Executive Director 6. Non-Executive Director 7. Non-Executive Director
| |||||||
b. | Initial notification/ Amendment | Initial Notification | |||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||
a. | Name | GENinCode Plc | |||||||
b. | LEI | 213800UX6TE7K65O2892 | |||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over Ordinary Shares of 1p each
N/A | |||||||
b. | Nature of the transaction | Grant of options under the 2021 Share Option Plan with time vesting conditions attached | |||||||
c. | Price(s) and volume(s) | Exercise Price(s) | Volume(s) | ||||||
| 1. | 3.7 pence | 2,431,082 | ||||||
2. | 3.7 pence | 2,216,062 | |||||||
3. | 3.7 pence | 1,462,524 | |||||||
4. | 3.7 pence | 554,016 | |||||||
5. | 3.7 pence | 387,423 | |||||||
6. | 3.7 pence | 387,423 | |||||||
7. | 3.7 pence | 172,188 | |||||||
d. | Aggregated information - Aggregated Volume - Price |
See above | |||||||
e. | Date of the transaction | 21 March 2025 | |||||||
f. | Place of the transaction | Outside a trading venue | |||||||
Related Shares:
Genincode